A personalized treatment protocol was more effective for management of acromegaly -- also known as gigantism -- than the usual trial-and-error approach, the ...

Single-ascending doses of MAR002 showed a favourable tolerability and safety profile with no drug-related safety signals ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Nearly all responders to a 26-week course of oral ...

Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY TM (paltusotine) ...

LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a ...

First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine ...

First subcutaneous, once-monthly octreotide for treatment of acromegaly For convenient self-administration with a pre-filled autoinjector pen LUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ ...

ACRO/TRUTH Provides Authentic Patient Perspectives, Peer-Reviewed Data on Treatment-Related Symptoms, Side Effects and Quality-of-Life Impact of Current Acromegaly Standard-of-Care SAN DIEGO, Aug. 08, ...

LONDON, Nov. 13, 2018 /PRNewswire/ -- This report offers an eight year forecast on the global Cushing's syndrome and Acromegaly Treatment market. The primary objective of the report is to offer ...